Monitor Dr. Reddy's Q1 FY27 earnings (due in ~2 weeks) for inventory write-down details and updated semaglutide revenue guidance. Track progress on root-cause analysis and re-validation timelines; any extension beyond September would further pressure the stock. Competitors like Sandoz and Aspen may accelerate their own GLP-1 launches, increasing competitive risk.
Drug in focus
RDY drug pipeline →semaglutide
◆ Mixed Named in this 6-K- Impact
- Phase
- Approved - Generic
- Time to market
- Already launched in India (March 2026) and Canada (May 2026), but supply halted until ~October 2026 due to API impurity. US market entry not expected until patent exclusivity ends ~2031-2032.
- Next catalyst
- None dated
What to watchWatch for Dr. Reddy's API remediation progress and the late-October 2026 supply restart timeline. The supply halt halved the FY27 production target from 12M to 6-7M pens and erased ~$678M in market cap. Any update on resolving the impurity issue, regulatory findings, or competitive dynamics (Apotex, USV) could move shares. US market entry (2031-2032 patent expiry) is the long-term prize but too distant to trade on now.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 15 $12.77entry
- T+1 · 4mo ago −0.55%α −0.01% · $12.70
- T+5 · 4mo ago −10.88%α −9.90% · $11.38
- T+20 · 3mo ago −2.98%α −5.32% · $12.39
- T+60 · 6w ago −4.46%α −7.00% · $12.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dr. Reddy's disclosed a manufacturing impurity issue in the scale-up of its semaglutide injection API, causing a halt in commercial supply for approximately three months. The company now expects to supply only 6-7 million pens in FY27 (down from prior guidance of ~12 million), with no patient safety impact or recall. This is a material negative for near-term revenue from its key GLP-1 product.
Key Facts
- Impurity (degradation) detected in finished drug product from a scale-up validation batch of semaglutide injection API.
- Commercial supply halted until process is fixed and re-validated; expected resumption late October/early November 2026.
- FY27 semaglutide pen guidance revised to 6-7 million pens (from prior ~12 million), with supply concentrated in Q3-Q4.
- No patient safety impact, no recall of previously supplied product, and no impact on oral semaglutide or existing regulatory filings.
- Potential write-down of inventory held at partner OneSource; no penalty clauses in partner agreements but down payments may be renegotiated.
Financial Impact
FY27 semaglutide injection revenue cut by roughly 40-50% vs prior expectations; potential inventory write-down of undisclosed amount; no penalty fees but possible renegotiation of customer advances.
Risk Factors
- Further delay if re-validation fails again, pushing commercial supply into 2027.
- Loss of market share to competitors (Sandoz, Aspen, Torrent) during the supply gap.
- Potential partner renegotiations or termination if supply reliability is questioned.
- Regulatory scrutiny if impurity issue escalates, though no agency notification required currently.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001575872-26-000504 |
| Document: 0001575872-26-000504-index.html | 0001575872-26-000504 |
| Document: 0001575872-26-000504.txt | 0001575872-26-000504 |
Track record
73 reports on RDY
6 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 6 of 11 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
- Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
- Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
- Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
- Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers